Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Trial Profile

Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jul 2018

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Oxaliplatin (Primary)
  • Indications Bladder cancer; Renal cancer; Ureteral-neoplasms; Urethral cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Aug 2018.
    • 23 Apr 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Jun 2020.
    • 23 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top